Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586859 | 0.88 | FABP6 (0.48) | FABP6GSK3BTRPV1ALDH1A1MAPT | |
| SCHEMBL16437217 | 0.88 | FABP6 (0.61) | FABP6GSK3BTRPV1CYP19A1ALDH1A1 | |
| SCHEMBL16014463 | 0.87 | FABP6 (0.47) | FABP6GSK3BTRPV1ALDH1A1MAPT | |
| SCHEMBL3594465 | 0.85 | PARP10 (0.54) | FABP6GSK3BPARP1PARP10PARP11 | |
| SCHEMBL16024278 | 0.85 | FABP6 (0.45) | FABP6GSK3BTRPV1ALDH1A1MAPT | |
| SCHEMBL25926813 | 0.84 | CYP19A1 (0.42) | CYP19A1ALDH1A1NPC1PLA2G1BNFKB1 | |
| SCHEMBL10274616 | 0.80 | ALDH1A1 (0.56) | FABP6GSK3BCYP19A1ALDH1A1NPC1 | |
| SCHEMBL20306282 | 0.78 | FABP6 (0.47) | FABP6GSK3BALDH1A1MAPTGAA | |
| SCHEMBL760553 | 0.78 | TRPV1 (0.55) | FABP6TRPV1ALDH1A1RAB9AMAPT | |
| SCHEMBL12078170 | 0.76 | PARP10 (0.54) | FABP6GSK3BCYP19A1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-2964642-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| EP-2964642-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9663494-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663494-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663494-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2964642-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| EP-2421854-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2421854-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122038-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122038-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | P2RX7, P2RX3, P2RX5 | FABP6 1025/4885GSK3B 1130/4885TRPV1 213/4885 |
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | FABP6 4550/4885GSK3B 198/4885TRPV1 3074/4885 |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | FABP6 4481/4885GSK3B 363/4885TRPV1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.